VistaGen Therapeutics, Inc. (VTGN)

From the record

VistaGen Therapeutics, Inc.'s filings since 2017 show 12 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2026-08-05); an auditor change (8-K item 4.01, 2 times, the latest 2024-07-12) (its current reports).

From the record

VistaGen Therapeutics, Inc.'s 5 filed years say what it did: revenue went from $1 million in fiscal 2021 to $1 million in fiscal 2026, up 3.1% a year; it rose in 2 of 4 years; the deepest fall was 56% from fiscal 2022 to fiscal 2025; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2026-03-31, VistaGen Therapeutics, Inc. lost about 196 cents for every dollar of shareholders' money. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 23.3% over the year (the filed statements).

From the record

VistaGen Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2026 ranks in the bottom 25% by size; a net margin of -5491.3% ranks in the bottom 15%; revenue growth of 3.4% a year over the last 3 filed years ranks in the bottom 44% (its annual reports).

From the record

VistaGen Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Singh, Shawn (President and CEO, as filed), filing under that title since 2011-05-25, 15.5 years (top 5% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 4.5 years (bottom 29%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

VistaGen Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $31 million against no long-term debt tagged leaves 63.4% of its assets as net cash, top 26% of its family; cash from operations less capital spending is -5235.3% of revenue (bottom 11%); research spending of 4332.1% of revenue (top 10%) (its annual report).

From the record

VistaGen Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 3.4% a year over the last three filed years against 3.1% over all 5, speeding up (top 29% of its family); the newest year grew 161.3% (top 12%); research spending grew 7.4% a year (top 43%) (its annual reports). VistaGen Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

VistaGen Therapeutics, Inc.'s newest year against its own record: revenue of $1 million in fiscal 2026 came in 243.7% above the $369 thousand its prior three years' pace pointed to (top 11% of its family); net income of $70 million against a prior three-year average of $43 million (bottom 21%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 22%) (its annual reports).